BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Blocking a Gene Stops Cancer Cells Spreading, University of East Anglia Study


1/24/2011 7:06:29 AM

University of East Anglia -- Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.

Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

The culprit gene – known as WWP2 - is an enzymic bonding agent found inside cancer cells. It attacks and breaks down a natural inhibitor in the body which normally prevents cancer cells spreading. The UEA team found that by blocking WWP2, levels of the natural inhibitor are boosted and the cancer cells remain dormant. If a drug was developed that deactivated WWP2, conventional therapies and surgery could be used on primary tumours, with no risk of the disease taking hold eleswhere.

Lead author Andrew Chantry, of UEA’s School of Biological Sciences, said the discovery could lead to the development of a new generation of drugs within the next decade that could be used to stop the aggressive spread of most forms of the disease, including breast, brain, colon and skin cancer.

“The late-stages of cancer involve a process known as metastasis - a critical phase in the progression of the disease that cannot currently be treated or prevented,” said Dr Chantry.

“The challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene. This is a difficult but not impossible task, made easier by the deeper understanding of the biological processes revealed in this study.”

The research was funded by UK-based charity the Association of International Cancer Research (AICR), with additional support from the Big C Charity and the British Skin Foundation.

Dr Mark Matfield, scientific co-ordinator of AICR, said: “This is a very exciting new discovery and a perfect example of the way that basic research into cancer can open up ways to develop new ways to treat cancer.”

The initial discovery was made while researchers were studying a group of natural cancer cell inhibitors called ‘Smads’.

Dr Surinder Soond, who spearheaded the experimental work in the laboratory, said: “This is a very novel and exciting approach to treating cancer and the spread of tumours which holds great potential.”

‘Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFß signalling and EMT’ by S Soond (University of East Anglia) and A Chantry (University of East Anglia) is published by Oncogene on January 24 2011.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES